In both neural stem cells and neuroblastoma cells, ID2 competes with bHLHs and E proteins for CDKN1C activation56 and, in GBM, a gene signature with high ID2 and low CDKN1C marks patients with a poorer prognosis49. This evidence concerns the gene CDKN1C and glioblastoma.